Ticlopidine-induced	ticlopidine-induced	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
:	:	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
three	three	O	O	O	O
Chinese	chinese	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
,	,	O	O	O	O
three	three	O	O	O	O
Chinese	chinese	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
ticlopidine-induced	ticlopidine-induced	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
were	were	O	O	O	O
reported	reported	O	O	O	O
and	and	O	O	O	O
another	another	O	O	O	O
13	13	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
English	english	O	O	O	O
literature	literature	O	O	O	O
were	were	O	O	O	O
reviewed	reviewed	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
attempted	attempted	O	O	O	O
to	to	O	O	O	O
find	find	O	O	O	O
underlying	underlying	O	O	O	O
similarities	similarities	O	O	O	O
,	,	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
identify	identify	O	O	O	O
appropriate	appropriate	O	O	O	O
treatment	treatment	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
complication	complication	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
but	but	O	O	O	O
one	one	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
over	over	O	O	O	O
60	60	O	O	O	O
years	years	O	O	O	O
old	old	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
6	6	O	O	O	O
who	who	O	O	O	O
died	died	O	O	O	O
were	were	O	O	O	O
all	all	O	O	O	O
older	older	O	O	O	O
than	than	O	O	O	O
65	65	O	O	O	O
.	.	O	O	O	O

Therefore	therefore	O	O	O	O
,	,	O	O	O	O
old	old	O	O	O	O
age	age	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
a	a	O	O	O	O
risk	risk	O	O	O	O
factor	factor	O	O	O	O
for	for	O	O	O	O
developing	developing	O	O	O	O
this	this	O	O	O	O
complication	complication	O	O	O	O
.	.	O	O	O	O

Agranulocytosis	agranulocytosis	O	O	OTHERS	I
occurred	occurred	O	O	O	O
3	3	O	O	O	O
-	-	O	O	O	O
20	20	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
ticlopidine	ticlopidine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
so	so	O	O	O	O
frequent	frequent	O	O	O	O
examination	examination	O	O	O	O
of	of	O	O	O	O
white	white	O	O	O	O
cell	cell	O	O	O	O
count	count	O	O	O	O
during	during	O	O	O	O
treatment	treatment	O	O	O	O
is	is	O	O	O	O
recommended	recommended	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
seemed	seemed	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
no	no	O	O	O	O
direct	direct	O	O	O	O
correlation	correlation	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
or	or	O	O	O	O
duration	duration	O	O	O	O
used	used	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
severity	severity	O	O	O	O
of	of	O	O	O	O
bone	bone	O	DISEASE	OTHERS	I
marrow	marrow	O	DISEASE	OTHERS	I
suppression	suppression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Treatment	treatment	O	O	O	O
for	for	O	O	O	O
ticlopidine-induced	ticlopidine-induced	O	O	O	O
aplastic	aplastic	O	DISEASE	OTHERS	I
anemia	anemia	O	DISEASE	OTHERS	I
with	with	O	O	O	O
colony-stimulating	colony-stimulating	O	O	O	O
factors	factors	O	O	O	O
seemed	seemed	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
little	little	O	O	O	O
effect	effect	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
fact	fact	O	O	O	O
that	that	O	O	O	O
5	5	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
6	6	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
received	received	O	O	O	O
concurrent	concurrent	O	O	O	O
calcium	calcium	CHEMICALS	O	OTHERS	I
channel	channel	CHEMICALS	O	OTHERS	I
blockers	blockers	CHEMICALS	O	OTHERS	I
died	died	O	O	O	O
,	,	O	O	O	O
should	should	O	O	O	O
alert	alert	O	O	O	O
clinicians	clinicians	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
more	more	O	O	O	O
cautious	cautious	O	O	O	O
when	when	O	O	O	O
using	using	O	O	O	O
these	these	O	O	O	O
two	two	O	O	O	O
drugs	drugs	O	O	O	O
simultaneously	simultaneously	O	O	O	O
.	.	O	O	O	O

